此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effect of Bilateral Greater Occipital Nerve Block on Headache After Intracranial Aneurysm Coiling

2026年11月13日 更新者:Ömer Keklicek、Konya City Hospital

Effect of Preoperative Ultrasound-Guided Bilateral Greater Occipital Nerve Block on Postoperative Headache Following Endovascular Coiling of Unruptured Intracranial Aneurysms: A Prospective, Randomized, Sham-Controlled Trial

Postoperative headache is a common complication following endovascular coil embolization of intracranial aneurysms and may increase analgesic requirements, impair patient comfort, and contribute to hemodynamic instability.

The greater occipital nerve (GON) has anatomical and functional connections with the trigeminocervical complex, suggesting that greater occipital nerve blockade may modulate headache-related pain pathways. However, the effectiveness of prophylactic greater occipital nerve block in patients undergoing elective endovascular coiling of unruptured intracranial aneurysms remains uncertain.

This prospective, randomized, sham-controlled, single-center clinical trial aims to investigate whether preoperative ultrasound-guided bilateral greater occipital nerve block reduces postoperative headache intensity during the first 24 hours following endovascular coil embolization.

A total of 76 patients will be randomly allocated in a 1:1 ratio to receive either ultrasound-guided bilateral greater occipital nerve block with 0.25% bupivacaine or bilateral superficial sham injections with 0.9% normal saline.

The active intervention will consist of 3 mL of 0.25% bupivacaine administered on each side in the fascial plane between the semispinalis capitis and obliquus capitis inferior muscles. The control intervention will consist of a superficial subcutaneous injection of 0.5 mL of 0.9% normal saline on each side.

All participants will receive standardized general anesthesia and postoperative multimodal analgesia.

The primary outcome will be the time-weighted average resting pain score during the first 24 postoperative hours, calculated from the area under the Numeric Rating Scale (NRS) pain score-time curve.

研究概览

研究类型

介入性

注册 (估计的)

76

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Ömer Keklicek, Principal Investigator
  • 电话号码:+905399291702
  • 邮箱:drokeklicek@gmail.com

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patients aged 18-65 years.
  • American Society of Anesthesiologists (ASA) physical status I-III.
  • Patients scheduled for elective endovascular coil embolization of a unilateral unruptured intracranial aneurysm under general anesthesia.
  • Ability and willingness to provide written informed consent.

Exclusion Criteria:

  • Refusal to provide informed consent or subsequent withdrawal of consent.
  • Ruptured intracranial aneurysm or acute subarachnoid hemorrhage requiring emergency intervention.
  • Clinical contraindications to greater occipital nerve block, including infection or skin lesions at the injection site, local anesthetic allergy, or anatomical conditions preventing safe needle placement.
  • Platelet count below 100,000/mm³, international normalized ratio (INR) greater than 1.5, activated partial thromboplastin time (aPTT) greater than 1.5 times normal, or clinically significant coagulopathy.
  • Antithrombotic or antiplatelet treatment that does not meet the predefined safety intervals for deep peripheral nerve blocks according to the ASRA 2025 and ESAIC/ESRA guidelines.
  • Moderate-to-severe preoperative headache, defined as a resting Numeric Rating Scale score of 3 or higher.
  • Known history of severe hypersensitivity or allergic reactions to local anesthetics.
  • Chronic opioid use, chronic pain syndrome, or regular analgesic use that may substantially interfere with postoperative pain assessment.
  • Uncontrolled hypertension or clinically significant uncontrolled cardiac arrhythmia.
  • Pregnancy or breastfeeding.
  • Neurological deficits, aphasia, impaired consciousness, cognitive impairment, or communication difficulties preventing reliable pain assessment using the Numeric Rating Scale.
  • Body mass index greater than 35 kg/m².
  • Clinical circumstances requiring initiation of intravenous unfractionated heparin within one hour after the planned study-related needle intervention.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Postoperative headache is a common complication following endovascular coil embolization of intracra

Participants assigned to the experimental group will receive preoperative ultrasound-guided bilateral greater occipital nerve block with 0.25% bupivacaine before induction of general anesthesia.

A total of 3 mL of 0.25% bupivacaine (7.5 mg) will be administered on each side into the interfascial plane between the semispinalis capitis and obliquus capitis inferior muscles. The total bilateral dose will be 15 mg of bupivacaine in 6 mL.

The intervention will be performed while the patient is awake and able to communicate, without routine deep sedation.

All participants will subsequently receive standardized general anesthesia and postoperative multimodal analgesia.

Ultrasound-guided bilateral greater occipital nerve block will be performed before general anesthesia induction using a high-frequency linear ultrasound transducer.

The greater occipital nerve will be identified between the semispinalis capitis and obliquus capitis inferior muscles. A 25-gauge, 50-mm echogenic needle will be advanced under continuous ultrasound guidance using an in-plane approach.

Following color Doppler assessment and negative aspiration, 3 mL of 0.25% bupivacaine (7.5 mg) will be injected slowly and incrementally on each side.

The total bilateral dose will be 15 mg of bupivacaine.

假比较器:Bilateral Superficial Sham Injection

Participants assigned to the control group will receive bilateral superficial subcutaneous sham injections with 0.9% normal saline before induction of general anesthesia.

Following the same general preparation, positioning, and ultrasound examination as the experimental group, 0.5 mL of 0.9% normal saline will be injected subcutaneously on each side of the occipital region using a short 27-gauge needle.

The total bilateral injection volume will be 1 mL.

The needle will not be advanced into the deep interfascial plane, and no injection will be performed around the greater occipital nerve.

All participants will receive standardized general anesthesia and postoperative multimodal analgesia.

A bilateral superficial subcutaneous sham injection will be performed before general anesthesia induction.

Following standardized positioning, skin antisepsis, and ultrasound examination, a short 27-gauge needle will be used to administer 0.5 mL of 0.9% normal saline subcutaneously on each side of the occipital region.

The total bilateral injection volume will be 1 mL.

The needle will not be advanced into the deep interfascial plane, and the greater occipital nerve will not be directly targeted.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Time-Weighted Average Resting Pain Score During the First 24 Postoperative Hours
大体时间:From postoperative hour 0 to postoperative hour 24

Postoperative resting pain intensity will be assessed using the 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain).

NRS scores will be recorded at postoperative hours 0, 2, 4, 6, 8, 12, and 24.

The area under the NRS pain score-time curve (AUC0-24) will be calculated using the linear trapezoidal method and divided by 24 hours to obtain the time-weighted average NRS score.

The resulting patient-level value will range from 0 to 10, with higher scores indicating greater overall postoperative pain intensity.

From postoperative hour 0 to postoperative hour 24

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年11月13日

初级完成 (估计的)

2027年11月2日

研究完成 (估计的)

2027年12月2日

研究注册日期

首次提交

2026年10月27日

首先提交符合 QC 标准的

2026年10月27日

首次发布 (实际的)

2026年11月2日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月13日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅